Form D · Biotechnology

Amprion, Inc.

San Francisco, CA · CIK 0001937140

Offering snapshot reported Sep 27, 2024 · SEC filing

Reported sold
$5.76M
Offering amount: $15M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 10, 2024
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$2.88M$5.76MSep 25, 2024: $3,761,381.00Sep 25, 2024Sep 27, 2024: $5,761,371.00Sep 27, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$3,761,381 → $5,761,371
  • Reported investors6 → 7

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 27, 2024Amendment$5,761,371$1,999,990vs Sep 25, 20247SEC filing
Sep 25, 2024Initial$3,761,381No comparison6SEC filing
Jul 15, 2022Initial$10,956,960No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-524986

Source: Form D, filed Sep 27, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Rahul Bhansali Director
Marc Chan Director
Peter Clinton Director
Russell Lebovitz Director, Executive
Kenneth Lehman Director
Claudio Soto Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
149 New Montgomery Street, 4 Th Floor
San Francisco, CA, 94105